Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/42990
Título: | Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB<inf>2</inf>receptor ligands with antagonist/inverse agonist properties | Autores/as: | Deiana, Valeria Gómez-Cañas, María Pazos, M. Ruth Fernández-Ruiz, Javier Asproni, Battistina Cichero, Elena Fossa, Paola Muñoz, Eduardo Deligia, Francesco Murineddu, Gabriele García-Arencibia, Moisés Pinna, Gerard A. |
Clasificación UNESCO: | 32 Ciencias médicas | Palabras clave: | CB(2) antagonism Cannabinoid receptors Molecular modelling Synthesis Tricyclic pyrazoles |
Fecha de publicación: | 2016 | Editor/a: | 0223-5234 | Publicación seriada: | European Journal of Medicinal Chemistry | Resumen: | Previous studies have investigated the relevance and structure-activity relationships (SARs) of pyrazole derivatives in relation with cannabinoid receptors, and the series of tricyclic 1,4-dihydroindeno[1,2-c]pyrazoles emerged as potent CB2 receptor ligands. In the present study, novel 1,4-dihydroindeno[1,2-c]pyrazole and 1H-benzo[g]indazole carboxamides containing a cyclopropyl or a cyclohexyl substituent were designed and synthesized to evaluate the influence of these structural modifications towards CB1 and CB2 receptor affinities. Among these derivatives, compound 15 (6-cyclopropyl-1-(2,4-dichlorophenyl)-N-(adamantan-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide) showed the highest CB2 receptor affinity (Ki = 4 nM) and remarkable selectivity (KiCB1/KiCB2 = 2232), whereas a similar affinity, within the nM range, was seen for the fenchyl derivative (compound 10: Ki = 6 nM), for the bornyl analogue (compound 14: Ki = 38 nM) and, to a lesser extent, for the aminopiperidine derivative (compound 6: Ki = 69 nM). Compounds 10 and 14 were also highly selective for the CB2 receptor (KiCB1/KiCB2 > 1000), whereas compound 6 was relatively selective (KiCB1/KiCB2 = 27). The four compounds were also subjected to GTPγS binding analysis showing antagonist/inverse agonist properties (IC50 for compound 14 = 27 nM, for 15 = 51 nM, for 10 = 80 nM and for 6 = 294 nM), and this activity was confirmed for the three more active compounds in a CB2 receptor-specific in vitro bioassay consisting in the quantification of prostaglandin E2 release by LPS-stimulated BV2 cells, in the presence and absence of WIN55,212-2 and/or the investigated compounds. Modelling studies were also conducted with the four compounds, which conformed with the structural requirements stated for the binding of antagonist compounds to the human CB2 receptor. | URI: | http://hdl.handle.net/10553/42990 | ISSN: | 0223-5234 | DOI: | 10.1016/j.ejmech.2016.02.005 | Fuente: | European Journal of Medicinal Chemistry [ISSN 0223-5234], v. 112, p. 66-80 |
Colección: | Artículos |
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.